At Karuna, our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions.
Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions.
Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don’t come easy, but are borne from passion and hard work. Together, we are working toward a goal bigger than ourselves.
We invite you to join us on LinkedIn and Twitter (@KarunaPharma) to stay up to date on our work.
Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions.
Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don’t come easy, but are borne from passion and hard work. Together, we are working toward a goal bigger than ourselves.
We invite you to join us on LinkedIn and Twitter (@KarunaPharma) to stay up to date on our work.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $169M
Founded date: 2009
Investors 4
| Date | Name | Website |
| - | PFM Health... | pfmhealths... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Sofinnova ... | sofinnova.... |
| - | NFLS - Piv... | pivotalbio... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.06.2019 | IPO | $89M | - |
| 01.04.2019 | Series B | $80M | - |
Mentions in press and media 18
| Date | Title | Description |
| 31.03.2026 | Amani Therapeutics: $25 Million Raised To Advance Neuropsychiatric Therapy AM-01 | Amani Therapeutics has raised $25 million in a Series A financing to advance its lead program, AM-01, a potential best-in-class therapy targeting serious neuropsychiatric disorders. The newly formed biotechnology company, backed by RTW Inve... |
| 24.12.2025 | Syremis Therapeutics Launches With $165 Million Series A Funding To Advance New Schizophrenia And Depression Drug Programs | Syremis Therapeutics, a clinical-stage biopharmaceutical company focused on mental health, has launched with $165 million in Series A financing to advance a neuropsychiatric pipeline rooted in clinically validated biology. The round was co-... |
| 19.12.2025 | Syremis Therapeutics Raises $165M in Series A Financing | Syremis Therapeutics, a Tel Aviv, Israel, and Boston, Massachusetts-based clinical-stage biopharmaceutical company developing novel medicines for the treatment of mental health, launched with $165m Series A financing. The round was co-led b... |
| 20.10.2024 | Monument Therapeutics: Precision Neuroscience Company Raises £1 Million | Monument Therapeutics, a precision neuroscience company, announced a further £1 million equity investment by the Forster Foundation, a charitable incorporated organization. This new funding builds on equity and non-dilutive funding announce... |
| 11.06.2024 | QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors | Industry veteran Williamson brings nearly three decades' experience as a leader in neuroscience R&D at organizations including Eli Lilly and Company, Lundbeck, Parexel, and Acadia Pharmaceuticals Former Karuna CFO Brown brings more than... |
| 09.04.2024 | ARCH funds neuropsychiatry company Seaport Therapeutics, led by the team behind Karuna Therapeutics | - |
| 14.12.2023 | Karuna Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia | - |
| 29.11.2023 | Karuna Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia | - |
| 25.02.2021 | Karuna Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides General Business Update | BOSTON--(BUSINESS WIRE)--Feb 25, 2021-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological condition... |
| 24.02.2021 | Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia | BOSTON--(BUSINESS WIRE)--Feb 24, 2021-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological condition... |
Show more